Article Information
History
- May 18, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Xiaomei Zhang1,8,
- Mei Zheng2,3,5,8,
- Te Liang1,8,
- Haijian Zhou4,5,8,
- Hongye Wang1,
- Jiahui Zhang1,
- Jing Ren1,
- Huoying Peng1,
- Siping Li1,
- Haodong Bian1,
- Chundi Wei1,
- Shangqi Yin2,3,5,
- Chaonan He2,3,5,
- Ying Han2,3,5,
- Minghui Li4,5,
- Xuexin Hou4,5,
- Jie Zhang6,
- Liangzhi Xie6,
- Jing Lv7,
- Biao Kan4,5,9,
- Yajie Wang2,3,5,9 and
- Xiaobo Yu1,9
- 1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
- 2Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China
- 3Department of Research Ward, Beijing Ditan Hospital, Capital Medical University, Beijing, China
- 4State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China
- 5Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital, Beijing, 102206, China
- 6Beijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological, Inc., Beijing, 100176, China
- 7Gobond Testing Technology (Beijing) Co., Ltd., Beijing, 102629, China
- ↵9Correspondence: xiaobo.yu{at}hotmail.com (X. Y.), wangyajie{at}ccmu.edu.cn (Y. W.), kanbiao{at}icdc.cn (B. K.)
↵8 These authors contributed equally to this work.
Posted May 18, 2021.
Inhibitor screening of Spike variants reveals the heterogeneity of neutralizing antibodies to COVID-19 infection and vaccination
